Osteoarthritis (OA) of the hip is a major cause of pain, disability and use of healthcare resources.[@R1] Although OA is multifactorial, it is known to have significant genetic contribution and a number of studies have attempted to dissect such contribution (see[@R2] for review).

The *DOT1L* gene encodes the DOT1-like histone H3 methyltransferaseis, a potentially dedicated enzyme for Wnt target gene activation in leukaemia recently shown to be associated with endochondral bone formation.[@R3]

A polymorphism (rs12982744) in *DOT1L* has been found to be strongly associated with minimum joint space width (minJSW) at the hip. This exact same single nucleotide polymorphism (SNP) was previously identified to be associated with increased height.[@R4] [@R5] The C allele associated with lower minJSW and lower height was associated with hip OA, although this association did not reach genome-wide significance (GWS) (OR 1.14, CI 1.06 to 1.22; p=1.5 **× **10^−4^).[@R3]

The GWS level of p\<5×10^−8^ is the threshold at which genetic associations are considered credible.[@R6] The aim of our study was to prove that common genetic variation in the *DOT1L* gene is important in hip OA at this level of confidence.

Genetic association data for rs12982744 and hip OA were derived from the Translational Research in Europe Applied Technologies for OsteoArthritis (TREAT-OA) consortium and combined with data from the UK (arcOGEN consortium), Estonia (Estonian Genome Center of the University of Tartu) and other studies (Nottingham, GOAL).[@R3] The total sample size was 9789 hip OA cases and 31 873 controls of which there were 4155 cases and 15 213 controls in male subjects and 5634 cases and 16 660 controls in female subjects. Summary OR was calculated using a fixed effects model. The individual study estimates and sample sizes are shown in [figure 1](#ANNRHEUMDIS2012203182F1){ref-type="fig"}. A full detailed description of each study cohort on recruitment, radiographic and clinical assessment is found in.[@R7] [@R8] Studies were approved by the relevant Ethics Committee and informed consent was obtained from all study participants.
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The results of the meta-analysis show that in male subjects the C allele of *DOT1L* rs12982744 is GWS with a 17% increased risk of hip OA (OR 1.17, 95% CI 1.11 to 1.23, p=7.8×10^−9^) with no observed heterogeneity (I^2^=0). In female subjects, the OR is 1.05 (95% CI 1.00 to 1.10, p=0.04) with I^2^=31%. The effect size estimate is significantly different between both sexes (p=0.003) with non-overlapping CIs. For both genders combined, the p value was 8.1×10^−8^ (I^2^=35%) ([figure 1](#ANNRHEUMDIS2012203182F1){ref-type="fig"}). The difference in effect size between genders is not surprising considering the sexual dimorphism of this trait: men have a larger mJSW and prevalence of hip OA rises specifically in women after menopause, suggesting a role of sex hormones in the disease process.

In this large-scale meta-analysis we show that the association between a *DOT1L* SNP and hip OA achieves GWS in male subjects strengthening the robustness of *DOT1L* as a risk factor for hip OA.

This makes *DOT1L* a potential therapeutic target for modulation and intervention in hip OA. This is relevant since small molecular inhibitors have been developed and a phase I trial has been started (<http://epizyme.com/programs/dot1l.asp>).

This result also highlights the greater statistical power of quantitative endophenotypes for genetic studies.
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